Pegylated interferon-α monotherapy leads to low response rates in HIV-infected patients with acute hepatitis C

Despite a rising incidence of acute HCV in patients infected with HIV, the optimal therapeutic strategy (pegylated interferon-α [PEG-IFN-α] monotherapy or in combination with ribavirin) is still under debate. A total of 23 HIV-infected patients were prospectively diagnosed with acute HCV and treated...

Full description

Saved in:
Bibliographic Details
Published in:Antiviral therapy 2011-01, Vol.16 (7), p.979-988
Main Authors: ARENDS, Joop E, VAN ASSEN, Sander, HOEPELMAN, Andy Im, STEK, Cari J, WENSING, Annemarie Mj, FRANSEN, Justin H, SCHELLENS, Ingrid M, SPIJKERS, Sanne Nm, MUDRIKOVA, Tania, VAN BAARLE, Debbie, SPRENGER, Herman G
Format: Article
Language:English
Subjects:
Adult
Alleles
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Antiviral Agents - administration & dosage
Antiviral Agents - therapeutic use
Biological and medical sciences
Cohort Studies
Female
Genotype
Hepacivirus - drug effects
Hepatitis C - complications
Hepatitis C - drug therapy
Hepatitis C - genetics
HIV Infections - complications
HIV Infections - drug therapy
Human viral diseases
Humans
Immunodeficiencies
Immunodeficiencies. Immunoglobulinopathies
Immunopathology
Infectious diseases
Interferon-alpha - administration & dosage
Interferon-alpha - therapeutic use
Interferons
Interleukins - genetics
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Polyethylene Glycols - administration & dosage
Polyethylene Glycols - therapeutic use
Polymorphism, Single Nucleotide
Prospective Studies
Recombinant Proteins - administration & dosage
Recombinant Proteins - therapeutic use
Recurrence
Ribavirin - administration & dosage
Ribavirin - therapeutic use
RNA, Viral - blood
RNA, Viral - genetics
Treatment Outcome
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
Viral hepatitis
Viral Load
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite a rising incidence of acute HCV in patients infected with HIV, the optimal therapeutic strategy (pegylated interferon-α [PEG-IFN-α] monotherapy or in combination with ribavirin) is still under debate. A total of 23 HIV-infected patients were prospectively diagnosed with acute HCV and treated with PEG-IFN-α2a monotherapy (180 μg/week) for 24 or 48 weeks. Add-on ribavirin was allowed from week 4 of therapy onwards. There were three patients who were not included for different reasons. Blood samples were routinely drawn for viral load measurement and IL28B polymorphism analysis. Spontaneous viral clearance occurred in 1 (4%) patient. Nineteen patients (13 genotype 1 and 6 genotype 4) received treatment with PEG-IFN-α monotherapy (3 with add-on ribavirin) resulting in a rapid virological response (HCV RNA
ISSN:1359-6535
2040-2058
DOI:10.3851/IMP1843